Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03412630 · ClinicalTrials.gov registry record · NA
Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab
A NA study, sponsored by ECOG-ACRIN Cancer Research Group.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03412630 is a NA study that was terminated before completion, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 1 participants.
The verdict
NCT03412630, a NA study, was terminated before completion, sponsored by ECOG-ACRIN Cancer Research Group.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase II trial studies how well computed tomography perfusion imaging works in predicting outcomes in patients with ovarian, fallopian tube, or primary peritoneal cancer who are receiving bevacizumab. Computed tomography perfusion imaging monitors the effects of the drug treatment on the blood flow to the tumor, and may help to predict whether a certain drug therapy is likely be successful in a patient with ovarian, fallopian tube, or primary peritoneal cancer.
Interventions
- RADIATION Computed Tomography Perfusion Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-12-13 |
| Est. Completion | 2020-07-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03412630
The ClinicalTrials.gov registry entry for NCT03412630 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Computed Tomography Perfusion Imaging is the first listed.
NCT03412630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03412630 about?
NCT03412630 is a clinical study titled "Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab". This phase II trial studies how well computed tomography perfusion imaging works in predicting outcomes in patients with ovarian, fallopian tube, or primary peritoneal cancer who are receiving bevacizumab. Computed tomography perfusion imaging monitors the effects of the drug treatment on the blood ...
What is the current status of trial NCT03412630?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2018-12-13. Estimated completion is 2020-07-22.
What interventions are being tested in trial NCT03412630?
The interventions under investigation include: Computed Tomography Perfusion Imaging (RADIATION).
Who is sponsoring clinical trial NCT03412630?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.